Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside
Hadeel Ahmed Kenoosh,Harikumar Pallathadka,Ahmed Hjazi,Aiman Mohammed Baqir Al‐Dhalimy,Sajad Ali Zearah,Pallavi Ghildiyal,Zuhair I. Al‐Mashhadani,Yasser Fakri Mustafa,Manar Mohammed Hizam,Ahmed Elawady
DOI: https://doi.org/10.1002/cbf.3954
2024-02-26
Cell Biochemistry and Function
Abstract:The messenger RNA (mRNA) vaccines have progressed from a theoretical concept to a clinical reality over the last few decades. Compared to conventional vaccination methods, these vaccines have a number of benefits, such as substantial potency, rapid growth, inexpensive production, and safe administration. Nevertheless, their usefulness was restricted up to now due to worries about the erratic and ineffective circulation of mRNA in vivo. Thankfully, these worries have largely been allayed by recent technological developments, which have led to the creation of multiple mRNA vaccination platforms for cancer and viral infections. The mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low‐cost manufacturing. The paper will examine the present status of mRNA vaccine technology and suggest future paths for the advancement and application of this exciting vaccine platform as a common therapeutic choice.
cell biology,biochemistry & molecular biology